Overview

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or E

Status:
NOT_YET_RECRUITING

Trial end date:
2032-09-11

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of Pumitamig in combination with chemotherapy versus Nivolumab in combination with chemotherapy in participants with previously untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma

Phase:

PHASE2

Details

Lead Sponsor:

Bristol-Myers Squibb

Collaborator:

BioNTech SE

Treatments:

Folfox protocol
Nivolumab